Identification of genomic determinants contributing to cytokine release in immunotherapies and human diseases

Lipei Shao, Alejandra Pelayo, Rongye Shi, Jinxia Ma, Hui Liu, Yihua Cai, Michaela Procházková, Robert Somerville, Sandhya R. Panch, Nirali N. Shah, David F. Stroncek, Ping JinJournal of Translational Medicine 2022 · DOI

TL;DR

This paper identifies the gene PFKFB4 and its role in regulating glycolysis as a key driver of cytokine release syndrome (CRS), a potentially life-threatening immune overreaction. By uncovering this link, the research suggests novel therapeutic targets for managing CRS in cancer immunotherapies and various human diseases.

What Problem Does This Paper Address?

Cytokine release syndrome (CRS) is a significant challenge in cancer immunotherapy, particularly with CAR T-cell therapies. It's an overactive immune response where the body releases excessive amounts of signaling molecules called cytokines, leading to widespread inflammation and potentially severe, even fatal, symptoms. While treatments exist, they aren't always effective, and some can have adverse effects like neurotoxicity. The current understanding of what triggers and drives CRS is incomplete, highlighting the need to identify specific molecular and cellular determinants to develop better preventative and therapeutic strategies. This paper aims to fill this gap by investigating the genomic factors associated with CRS.

Methods

The researchers employed the Nanostring nCounter gene expression platform, a high-fidelity method for simultaneously detecting hundreds of mRNA molecules. They analyzed RNA extracted from 43 pre-infusion CD22 CAR T-cell products. Gene expression data was processed using nSolver Analysis Software and Partek Genomics Suite for normalization and batch effect removal. Statistical analysis involved comparing gene expression and pathway activity between groups of patients with different CRS grades. Gene set variant analysis (GSVA) was used to assess the activity of custom pathways. Publicly available gene-expression datasets were utilized for validation across various human diseases and tumor types.

Datasets

  • Primary Dataset: 43 pre-infusion CD22 CAR T-cell products.
  • Public Datasets for Validation:
    • COVID-19 cohorts (GEO platform)
    • Influenza infections (H1N1, H3N2, Influenza B)
    • Autoimmune diseases (Systemic Lupus Erythematosus - SLE, Systemic Juvenile Idiopathic Arthritis - SJIA)
    • Tumor tissues (TIMER2.0 database, various cancer types)
    • Additional public datasets for gene expression profiles of whole blood, peripheral blood mononuclear cells, and monocytes.

Key Insights and Ideas

  • PFKFB4 as a CRS Driver: The study strongly implicates PFKFB4 as a key gene involved in mediating cytokine release. Its expression levels directly correlate with the severity of CRS.
  • Glycolysis as the Mechanism: The research proposes that PFKFB4 exerts its effect by regulating glycolytic activity. This metabolic pathway appears to be upregulated in cells associated with higher CRS grades.
  • Cross-Disease Relevance: The findings aren't limited to CAR T-cell therapy. PFKFB4 and glycolytic pathway dysregulation were also observed in other conditions known to cause CRS, such as COVID-19, influenza, and autoimmune diseases, underscoring the broad applicability of these insights.
  • Tumor Microenvironment Connection: PFKFB4's role extends to the tumor microenvironment, where it's linked to increased pathological stages and potentially tumor metastasis, suggesting a dual role in inflammation and cancer progression.
  • Immune Cell Modulation: PFKFB4 appears to influence the tumor immune microenvironment by negatively correlating with CD8+ T cells and M2 macrophages while positively correlating with neutrophils, CAFs, and MDSCs, suggesting it promotes a pro-inflammatory state.

Key Results

  • PFKFB4 Upregulation: PFKFB4 gene expression was found to be gradually upregulated in CAR T-cells from patients who developed increasing grades of cytokine release syndrome (CRS). This trend was also observed in a separate CD19 CAR T-cell trial.
  • Glycolytic Pathway Activation: Glycolytic pathway activity showed a similar increasing trend with higher CRS grades. Genes involved in glycolysis, including key regulators like GPI, PGK1, and PKM, were positively correlated with PFKFB4 expression.
  • Validation in Disease Cohorts: PFKFB4 expression was significantly upregulated in patients with COVID-19, particularly those with severe symptoms. It was also elevated in influenza-infected individuals and patients with severe SLE and active SJIA.
  • Tumor Association: PFKFB4 was significantly upregulated in multiple cancer types (e.g., liver hepatocellular carcinoma, renal cancer) and correlated with higher pathological stages. Glycolytic pathway activity was also enhanced in later stages of these tumors.

Limitations and Future Work

  • Sample Size: The study analyzed a relatively small number of CD22 CAR T-cell products (n=43). The authors suggest that analyzing more samples would increase statistical power and potentially identify more candidate genes.
  • Public Dataset Limitations: While public datasets were used for validation, the authors acknowledge that the lack of control over their collection and background information can make it difficult to fully explain certain findings (e.g., PFKFB4 upregulation in SLE without corresponding glycolytic activity changes).
  • Cytokine Data: The study did not obtain serum cytokine levels from patients, which would have provided direct evidence of which cytokines were mediated by PFKFB4.
  • Future Directions: The paper strongly advocates for the development of drugs targeting PFKFB4 and the glycolytic pathway for CRS treatment. Further research is needed to elucidate the precise mechanisms by which PFKFB4 interacts with cytokine gene expression, potentially by identifying the transcription factors involved. Investigating how PFKFB4 engages in cytokine release in various immune cells is also recommended.

Summary updated

Abstract

Our data strongly suggests that PFKFB4 acts as a driving factor in mediating cytokine release in vivo by regulating glycolytic activity. Our results suggest that it would beneficial to develop drugs targeting PFKFB4 and the glycolytic pathway for the treatment of CRS.
BibTeX
@article{shao2022identification,
  author = {Lipei Shao and Alejandra Pelayo and Rongye Shi and Jinxia Ma and Hui Liu and Yihua Cai and Michaela Procházková and Robert Somerville and Sandhya R. Panch and Nirali N. Shah and David F. Stroncek and Ping Jin},
  title = {{Identification of genomic determinants contributing to cytokine release in immunotherapies and human diseases}},
  journal = {Journal of Translational Medicine},
  year = {2022},
  doi = {10.1186/s12967-022-03531-3},
}
Figure